What is Avinger?
Headquartered in Redwood City, California, Avinger, Inc. operates as a commercial-stage medical device innovator specializing in image-guided, catheter-based systems. The company's core value proposition lies in its lumivascular technology, which uniquely integrates optical coherence tomography with interventional catheters. This allows physicians to perform real-time intravascular imaging during complex procedures. By providing tools such as the Ocelot, Tigereye, and Pantheris devices, Avinger enables interventional cardiologists, vascular surgeons, and radiologists to treat peripheral artery disease with unprecedented precision. The company's focus on removing arterial plaque while maintaining clear visualization represents a significant advancement in minimally invasive vascular surgery, positioning it as a key player in the global healthcare technology landscape.
How much funding has Avinger raised?
Avinger has raised a total of $125M across 6 funding rounds:
Debt
$10.5M
Stock Offering
$65M
Debt
$33M
Debt
$10M
Stock Offering
$4.5M
Debt
$2M
Debt (2013): $10.5M, investors not publicly disclosed
Stock Issuance/Offering (2015): $65M, investors not publicly disclosed
Debt (2015): $33M supported by CRG
Debt (2016): $10M featuring CRG LP
Stock Issuance/Offering (2019): $4.5M, investors not publicly disclosed
Debt (2020): $2M with participation from PPP
Key Investors in Avinger
CRG
CR Group L.P. is a global investment firm focused on enhancing healthcare through flexible growth capital solutions, specializing in credit and equity investments across life sciences and healthcare services.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Avinger?
With the recent strategic investment, Avinger is well-positioned to accelerate the development of its pipeline, including the IMAGE-BTK system designed for below-the-knee lesion treatment. The company's strategic roadmap emphasizes the expansion of its commercial footprint in the United States and Germany, leveraging its existing portfolio to capture greater market share. By focusing on clinical efficacy and the refinement of its real-time imaging capabilities, Avinger aims to address the unmet needs of patients suffering from advanced PAD. Future growth will likely be driven by continued investment in R&D and the optimization of its sales channels to ensure that its lumivascular products remain the standard of care for vascular interventionists seeking high-fidelity diagnostic and therapeutic outcomes.
See full Avinger company page
